MRI CONTRAST AGENT METHODS TO ASSESS TUMOR ANGIOGENESIS

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这个gcrc支持的项目需要解决NIH拨款的特定目标4：特定目标4：评估CBV， CBF和血管形态学测量的潜力，以跟踪脑肿瘤患者的肿瘤生长，进展和对治疗的反应。我们证明了使用一种新的GE/SE成像方法获得总（GE）和微血管（SE） CBV以及血管大小信息（DR2*/DR2）的可行性。GE CBV和比值在低级别肿瘤和高级别肿瘤之间存在显著差异，其结果取决于正确考虑造影剂外渗效应。现在，我们建议获得脑肿瘤患者随时间和放疗前后的多参数数据集（CBV， CBF，血管口径），并将其与相关免疫组化（IHC）标志物进行比较。我们假设每个参数将在预测肿瘤血管生成、肿瘤进展和治疗反应方面发挥独特而互补的作用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This GCRC-supported project entails addressing Specific Aim 4 of the NIH grant: Specific Aim 4: To evaluate the potential of CBV, CBF and vascular morphology measurements to track tumor growth, progression and response to treatment in brain tumor patients. We demonstrated the feasibility of using a novel GE/SE imaging method to obtain measures of total (GE) and microvascular (SE) CBV, along with vessel size information (DR2*/DR2). The GE CBV and ratio showed significant differences between low and high-grade tumors, a result dependent on the proper consideration of contrast agent extravasation effects. Now, we propose to obtain multiparameter data sets (CBV, CBF, vessel caliber) from brain tumor patients over time and before and after radiation therapy, and compare them to relevant immunohistochemical (IHC) markers. We hypothesize that each parameter will play a unique yet complementary role in predicting tumor angiogenesis, tumor progression and response to therapy.